Fagron supplies products, services to professionals and institutions in the healthcare sector in Europe, the U.S.A. and Brazil. Co.'s activities are subdivided into four divisions. Through Fagron, Co. offers products and concepts for pharmaceutical compounding. Through Arseus Dental, Co. supplies dental products and concepts to dentists and dental laboratories in Belgium, the Netherlands, France, Germany and Switzerland. Through Arseus Medical, Co. supplies medical and surgical products to specialists, elderly homes, homecare nurses and hospitals in Belgium and the Netherlands. Through Corilus, Co. supplies ICT total solutions for medical specialists in Belgium, the Netherlands and France.
  • TickerFAGR
  • ISINBE0003874915
  • ExchangeEuronext Brussels
  • SectorHealth Care Equipment & Services
  • CountryBelgium

Analysts

Fagron Nv: 1 director bought

A director at Fagron Nv bought 3,000 shares at 14.633EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board mem...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Bottoms-up view on developed int'l, part two Big Picture: Our outlook remains neutral on the MSCI ACWI ex-U.S. index (when priced in local currency) while horizontal consolidation continues. On the other hand, we are negative on broad global ex-U.S. markets when priced in USD... see charts below. In today's report we take a bottoms-up approach to developed ex-U.S. equities, highlighting stocks that present attractive buy opportunities at current levels. Specifically we present actionable stocks within the Communications, Health Care, Manufacturing, Materials, Technology, Transportation, and U...

Fagron Nv: 1 director bought

A director at Fagron Nv bought 3,000 shares at 14.633EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board mem...

Alan Vandenberghe ...
  • Lenny Van Steenhuyse
  • Marcel Achterberg
  • Ruben Devos
  • Wim Hoste

Morning Note: ASM NA, FAGR BB, GVNV NA, MDXH BB, REC BB, SOLB BB, TNET BB, WKL NA

ASM International: Upgrade after very strong start to FY20 Fagron: Sanofi to spin out API manufacturer GrandVision: Good growth but soft margins MDxHealth: 4Q19 shows return to growth Recticel: Preview FY results: quid Automotive Interiors? Solvay: 4Q in line with CSS, FY20 guidance slightly light Telenet: Creation of JV between Eltrona - SFR-Coditel in LUX Wolters Kluwer: Great set of results, expect 3-5% EPS upgrades Various: BEL20: Who's in, who's out?

Bart Cuypers ...
  • Cedric Duinslaeger
  • Jason Kalamboussis
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs
  • Wido Jongman
  • Wim Hoste

Morning Note: AGN NA, AKZA NA, BEFB BB, BRNL NA, COFB BB, EXM BB, FAGR BB, REL LN, RTL BB, SBMO NA

AEGON: Selling the silverware tells it all: Downgrading Akzo Nobel: Feedback Investor Seminar Befimmo: FY19 Results as expected Brunel International: Home markets pressured, other regions growing Cofinimmo: FY19 Results in line with expectations EXMAR: Corona delays restricted cash release Fagron: Narrative shifting from opportunities to risks RELX Group: 7% EPS growth estimate in 2020, TP goes to £ 19.5 RTL Group: M6 results better than exp. on strong ad revs SBM Offshore: FY19 Conf Call Feedback

ING
ING Helpdesk

Benelux Morning Notes

AEGON: Capital generation sound, but slight miss on SII and earnings. Ageas: Setting a new high bar for DPS €2.70 (INGF). AkzoNobel: Outlines ambitions for 2021-23F. Arcadis: good results on the back of 4Q19 organic revenue growth. Barco: Better than expected update on Entertainment. DSM: When the going gets tough… Euronext: low to mid-single digit negative earnings revisions. Fagron: FY2019 in line, Wichita below sales and SKU targets. KBC: Delivering on capital return promise. Kinepolis: New cinema openings possible in Belgium from August 2021. NN Group: Solid message on ca...

Alan Vandenberghe ...
  • Bart Cuypers
  • Cedric Duinslaeger
  • Guy Sips
  • Jason Kalamboussis
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs
  • Thomas Couvreur
  • Wido Jongman
  • Wim Hoste

Morning Note: ABN NA, AD NA, ARCAD NA, BAR BB, DSM NA, ENX FP, FAGR BB, INTO BB, KIN BB, MONT BB, NN NA, REN NA, SBMO NA, SIP BB, VPK NA

ABN Amro: 4Q CC: some positives, but slippery outlook Ahold Delhaize: Lifting estimates post FY19 reporting Arcadis: Solid 4Q19 operational performance Barco: On a sustainable profitable growth path DSM: 4Q EBITDA +3% underlying, 1% above estimates Euronext: 4Q19: Solid top line; one-offs weighing on result Fagron: Topline slightly below expectations, strong margins IO&W: FY19 Results better than expected Kinepolis: Free to open new Belgian cinemas from August’21 Montea: FY19: All targets achieved NN Group: Strong results, SBB, upgrading to BUY RELX Group: Slightly better FY results, Volatile ...

FAGRON loses on its star level and is downgraded to Slightly Positive

The independent financial analyst theScreener just slightly lowered the general evaluation of FAGRON (BE), active in the Medical Equipment industry. The title has lost a star(s) at the fundamental level and now shows 3 out of 4 stars. Its exposure to market risk remains nonetheless the same and can be still described as defensive. theScreener slightly downgrades the general evaluation to Slightly Positive for the title on account of the lost star(s). As of the analysis date February 25, 2020, the closing price was EUR 20.00 and its potential was estimated at EUR 23.03.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch